DISCOVERY: Georgia State Honors College Undergraduate
Research Journal
Volume 4

Article 4

2019

Analysis of the Genetic and Neurological Components of Opioid
Addiction, with Public Health Perspectives of the Opioid Epidemic
in the United States of America
Janhavi A. Dubhashi
Georgia State University

Follow this and additional works at: https://scholarworks.gsu.edu/discovery
Part of the Genetics Commons, Integrative Biology Commons, Molecular Genetics Commons,
Neuroscience and Neurobiology Commons, and the Other Public Health Commons

Recommended Citation
Dubhashi, Janhavi A. (2019) "Analysis of the Genetic and Neurological Components of Opioid Addiction,
with Public Health Perspectives of the Opioid Epidemic in the United States of America," DISCOVERY:
Georgia State Honors College Undergraduate Research Journal: Vol. 4, Article 4.
DOI: https://doi.org/10.31922/disc4.4
Available at: https://scholarworks.gsu.edu/discovery/vol4/iss1/4

This Article is brought to you for free and open access by ScholarWorks @ Georgia State University. It has been
accepted for inclusion in DISCOVERY: Georgia State Honors College Undergraduate Research Journal by an
authorized editor of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.

Analysis of the Genetic and Neurological Components of Opioid Addiction, with
Public Health Perspectives of the Opioid Epidemic in the United States of
America
Cover Page Footnote
Dr. Robert Maxwell

This article is available in DISCOVERY: Georgia State Honors College Undergraduate Research Journal:
https://scholarworks.gsu.edu/discovery/vol4/iss1/4

INTRODUCTION
In the United States of America, the use and abuse of opioids has reached epidemic proportions.
In 2017, the U.S. Department of Health and Human Services declared the opioid crisis a public
health emergency as the rates of overdose deaths continued to rise. The same year as this
declaration, more Americans died due to drug overdoses than the number of deaths from
HIV/AIDS at the peak of the epidemic in 1995. This epidemic has killed more Americans than
the total number of American deaths in the Vietnam War. The primary driver of these overdose
deaths is due to opioids, both prescription painkillers such as morphine and oxycodone and illicit
drugs such as heroin. This paper looks to analyze the various contributing factors leading to
addiction, and the implications on society with such a large population of Americans facing
addiction.
NERVOUS SYSTEM INTRODUCTION
The nervous system is divided into the central nervous system (CNS) which contains the brain
and spinal cord, and the peripheral nervous system (PNS) which includes the nerves that travel
throughout the body. Drug abuse impacts the CNS and many functions involved in heart rate,
sleeping, and breathing through the brain stem; emotions, including happiness through the limbic
system; and decision-making abilities through the cerebral cortex. The different parts of the
human brain can communicate with each other via neurons and neurotransmitters. Neurons are
brain cells used to relay signals, and neurotransmitters are the chemical messengers that are the
signals. Each neuron has different receptors, which allow for the binding of a specific
neurotransmitter; once bound, an action potential can occur which is the propagation of the
signal down the neuron. There are many different types of neurotransmitters but all fall into two
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categories: excitatory or inhibitory. Excitatory neurotransmitters will increase the likelihood of a
response while inhibitory neurotransmitters do the opposite.
OPIOID NEUROTRANSMITTERS
There are four main classes of opioids: natural opiates, semi-synthetic opiates, fully synthetic
opiates, and endogenous opiates. Synthetic and semi-synthetic opioids can interfere with the
typical neural pathways involved in sending, receiving, and processing information that allows
the different areas of the brain to communicate with each other. The naturally produced
endogenous opioids are created in the brain and work to block pain. The opioid epidemic is
focused around exogenous opioids, which are chemical signals that are not naturally made by the
human body and are instead often prescribed by a healthcare provider. Exogenous opioids are
similar in structure to endogenous opioids, and therefore can activate receptors in the brain
resulting in the same effects as endogenous opioids. Exogenous opioids can alter certain essential
areas of the brain, such as the brain stem, cerebral cortex, and the limbic system (NIDA, 2014).
PAIN SENSATION
One form of communication between neurons involves pain sensation, and many of the pain
pathways utilize opioid neurotransmitters. Neurons sense injuries that occur to the skin and
muscles and then signal other neurons in the central nervous system. Pain nerves in the body
begin to fire less intensely once natural opioids such as endorphins and enkephalins bind to
receptors. However, in instances when there is chronic pain, pain signals are constant. Natural
endorphins are not sufficient to deal with this long-lasting chronic pain, and often prescription
opioids are prescribed (Akpan & Griffin, 2017).
Opioids, both endogenous and exogenous, affect neural pathways that are involved in
pain and pleasure perception; these pathways include the dopaminergic and GABA-nergic
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pathways. Opioids can hijack the normal functioning of the reward pathway and activate neurons
because the chemical structure resembles that of a natural neurotransmitter. Dopamine is an
excitatory neurotransmitter that is present in the mesolimbic dopamine pathway of the brain and
regulates feelings of pleasure and emotion (NIDA, 2014). Opioids function to overstimulate
neural systems and flood the reward system of the brain with dopamine, releasing 2-10 times the
amount of dopamine than what is released on a regular basis (Di Chiara & Imperato, 1988).
There are two main ways that the brain works to return to homeostatic levels of dopamine - there
will be an overall decreased production of dopamine, or there will be an overall decreased
production of the number of dopamine receptors. Abuse of exogenous opioids can lead to a
down-regulation of dopamine receptors. This decrease in dopamine signaling leads to those who
have been taking opioids being unable to experience even daily pleasures (NIDA, 2014).
While increasing levels of dopamine, opioids also work to relieve pain in the body by
suppressing GABA neurotransmission (Basbaum & Fields, 1984). GABA is an inhibitory
neurotransmitter found throughout the brain and spinal cord that is primarily involved in
controlling thinking and perceiving. By decreasing the functionality of the inhibitory
neurotransmitter and increasing the excitatory neurotransmitter, opiates increase feelings of
pleasure to such intensity that once an individual stops taking the drug, feelings of intense
withdrawal occur. In normal body functioning, when dopamine levels increase, GABA levels
tend to increase as well to bring the body back to a homeostatic balance. Opiates, including
heroin and morphine, function as agonists at the opioid receptors and activate dopamine in the
ventral tegmental area by inhibiting GABAergic neurons (Johnson & North, 1992). Overall, this
disinhibition leads to an increase in dopamine neurotransmission and a decrease in GABA
neurotransmission, which amplifies the signal elicited by dopamine.
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The need to elicit increased dopamine levels forms the basis for the transition from
normal reward impulses to addiction. With the consistently elevated levels of dopamine that are
present with increased intake of drugs, the level of dopamine receptors decreases, and the levels
of presynaptic dopamine transporters also decrease as a compensatory mechanism (Volkow et
al., 1993). When opioid drugs are administered repeatedly, the ability of neuronal cells to
produce endogenous opioids is inhibited, which is part of the reason that withdrawal symptoms
occur with such extreme discomfort (NIDA, 2014).
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Figure 1: Pathway for Opioid Dependence
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MOLECULAR MECHANISMS OF OPIOID TOLERANCE
The inhibition of the neural cells to produce these endogenous opioids also leads to opioid
tolerance. Tolerance is when the effect of a drug is no longer as strong as it was when first taken,
leading to higher doses required to induce a similar effect (NIDA, 2014). Substance addiction
occurs when there has been substance abuse at such a repetitive level that the normal circuitry of
reward and behaviors is corrupt (Di Chiara & Imperato, 1988).
Once there are excess exogenous opiates in the nervous system, the neurons begin to
adapt. The neurons that normally secrete GABA following opioid exposure now begin to
produce three to four times more cyclic AMP. Cyclic AMP is part of a second messenger system
and functions in intracellular signaling, allowing the neuron to reach threshold potential. Once
there is excess cAMP, there is excess neural firing. This adaptation of increased cAMP
production will continue even when there are no opioids present, and lead to excess GABA
neurotransmitter signaling in the brain (Akpan, N., & Griffin, J. 2017).
Calcium also plays a role in the development of opioid tolerance. When there is an acute
administration of opioid agonists, there is a reduction in the calcium content in synaptic vesicles.
Since calcium is required for an action potential to begin, the reduced calcium intake caused by
opioids will indirectly cause an increase in potassium exiting the cell, leading to a shortening of
the repolarization period and a shortening of the action potential duration. (Chahl, 1996). There
is a correlation between the ineffective regulation of cAMP caused by opioids and the tolerance
induced at a molecular level to opioids. When there are chronic levels of morphine exposure,
there is the potential for the upregulation of adenylyl cyclase and protein kinase A (PKA)
because opioid receptors couple to adenylate cyclase, which can lead to an inhibition of
neurotransmitter release as depicted in Figure 2 (Dang & Christie, 2012).
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Figure 2: Mechanism of Opioid Neurotransmitter Release
This image depicts the proposed impact opioids have on neurons. By inhibiting calcium entry and
enhancing potassium exiting, there is an inhibition of neurotransmitter release. Another
mechanism is the inhibition of adenylate cyclase to have decreased levels of cAMP (Chahl, 1996).

DOPAMINE REWARD PATHWAY
In 1954, Olds and Milner conducted experiments that established the foundational understanding
of reward mechanisms in the brain. The researchers gave rodents the option to repeatedly
administer electrical stimulation to the brain. The regions that elicited “pleasure,” such as the
nucleus accumbens and the septum, would result in continual voluntary stimulation by the mice
themselves. The major pathway identified in this reward system was the mesolimbic pathway,
also known as the dopamine reward pathway.
The mesolimbic pathway (Figure 3) originates from a group of neurons in the ventral
tegmental, area (VTA) and terminates in either the nucleus accumbens of the ventral striatum,
the amygdala, bed nucleus of stria terminalis, lateral septal area, or lateral hypothalamus
(Gardner & Ashby, 2000). The nucleus accumbens is believed to play an important role with
7

reward while the amygdala is associated with emotion (S.R.W. Stott, S.-L. Ang, 2013). All
rewarding stimuli increase the concentrations of mesolimbic dopamine in the extracellular
regions. When drugs activate the neurons in the VTA, there is a release of dopamine into the
nucleus accumbens leading to feelings of pleasure (Friedman, D.P. & Rusche S., 1999). Opiates
bind to opiate receptors that send a signal to the dopamine terminal to release more dopamine.
The activation of opiate receptors leads to a decrease of GABA release, which typically
functions to inhibit dopamine (NIDA, 2007). Opiates decrease pain and increase pleasure, which
overall leads to a very addictive neurological combination.

Figure 3: The Mesolimbic Pathway
Dopaminergic pathways.svg by Patrick J. Lynch is licensed under CC-BY 3.0.
This pathway is also referred to as the dopaminergic pathway and consists of neurons that have
cell bodies that run the entire length of this pathway. These neurons produce dopamine and can
send this signal to their destinations.
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There are many different effects of dopamine, and the various effects are mediated by
five different transmembrane G-protein coupled receptor subtypes. The D1-receptors activate
adenylyl cyclase, and the D2-receptors inhibit adenylyl cyclase and activate potassium channels
leading to an overall potassium efflux, which causes hyperpolarization in the local potentials in
the cell (Missale et al., 1998). The potassium efflux is counteracting the calcium influx, thus
reducing the amount of neurotransmitter released.
OPIOID PATHWAY
Opioids function by attaching themselves to opioid receptors present on neurons in the brain,
spinal cord, gastrointestinal tract, and other organs in the body. Once the opiate attaches to these
receptors, the perception of pain is reduced; however, there are side effects caused by opiates
such as drowsiness, respiratory depression, mental confusion, nausea, and constipation due to the
widespread presence of opiate receptors in various neural and physiological pathways (Mattoo,
2009).
There are three different types of transmembrane opioid receptors, μ, κ, and δ, to which
an opioid can bind. Opioid receptors can be activated by endogenous opioid chemicals such as
endorphins and enkephalins or by exogenous chemicals such as prescription opiates (NIDA,
2014). All three receptors are located in pain-modulating pathways within the brain, including
the medulla, locus coeruleus, the limbic system, the midbrain, cortical structures, and the
periaqueductal gray area (McNicol et al., 2003). Of the three receptors, the μ receptor is
primarily responsible for the relative effects of opioids and opiate addiction (Akpan, N., &
Griffin, J. 2017).
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Figure 4: Site of Action for Opioids
In this figure, there are two pathways, a gray pathway, which depicts pain transmission from the
PNS to the CNS, and a red pathway, which depicts the pain-modulating neurons in the medulla
and the mid brain (Al-Hasani & Bruchas, 2011).

Activation of the opioid receptor by an exogenous opioid causes the second messenger
system of inhibitory G-protein coupled receptors to be activated. The opioid itself is the first
messenger and never enters the cell body, but instead binds to a receptor, which causes a series
of activations and inhibitions in the rest of the signaling pathway. The binding of the opioid to
the opioid receptor leads to a conformational change in the receptor, activating the coupled Gprotein. The Gi receptor is the mechanism most opiates utilize, and this complex leads to a
dissociation between the Giα and Giβγ subunits of the G-protein. The Giα molecule inhibits the
activation of adenylyl cyclase. Adenylyl cyclase is the enzyme that converts ATP to PPi and
cAMP (Childers & Snyder, 1978). The inhibition of adenylyl cyclase leads to a reduction in the
cAMP-dependent calcium influx, impacting the polarization of the cell. This disassociation also
leads to the interaction of Gα protein with Kir3, which is a rectifying potassium channel. By
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deactivating the potassium channel, the cell becomes hyperpolarized, and the neural activity will
be dampened (Ippolito, Temkin, Rogalski, & Chavkin, 2002). A similar mechanism occurs for
calcium channels, where the disassociated Gβγ subunit directly binds to the channel and reduces
the opening of voltage-gated calcium channels (Zamponi & Snutch, 2002). As a result, there is a
coupling to potassium channels and a negative modulation for calcium channels for opioid
receptors (Al-Hasani & Bruchas, 2011).

Figure 5: Opioid Receptor Signaling
This cartoon depicts the common molecular pathway that opioid receptors use. The arrows refer to
activation while the T lines depict inhibition of a signaling molecule. The MAPK signaling molecules that
are activated are all kinases that will phosphorylate molecules downstream (Al-Hasani & Bruchas, 2011).
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SUMMARY OF BRAIN ANATOMY INVOLVED WITH ADDICTION
The parts of the brain that are involved with the reward pathway are the same as the parts of the
brain that are involved with addiction. The release of dopamine in the nucleus accumbens leads
the hippocampus to create a conditioned response to the opiate. Along with the hippocampus, the
amygdala is typically related to the memory of emotionally arousing events. The hesitation and
fear present with new stimuli and the assignment in reward values for existing stimuli is done by
this part of the brain. The memories created by these two parts of the brain lead to a conditioned
response whenever environmental cues are encountered that remind the individual of their
previous drug consumption. (Elliott et al., 2000).
The anterior cingulate is involved with emotional self-control, error detection, and
adaptive responses to changing conditions. The anterior cingulate also plays a role in processing
conflicts and performance monitoring. The bed nucleus of the stria terminalis (BNST) is located
in the extended amygdala and is sensitive to dopamine stimulation. The BNST is involved with
the autonomic and behavioral reactions such as the stress response to fearful stimuli.
Experiments have shown that this part of the brain is involved in the reinstatement of a drug
directly after experiencing a painful stimulus. The dorsolateral prefrontal cortex (DLPFC) is
involved with the control and regulation of cognitive activities. The holding/maintaining working
memory for the short-term storage is conducted by the DLPFC. The hippocampus is important
for acquiring new factual information and forming new memories. Alzheimer’s disease and other
memory impacting diseases as well as anterograde amnesia are typically the results of damage to
the hippocampus. (Elliott et al., 2000).
The orbitofrontal cortex (OFC) is involved when faced with unpredictable situations and
is implicated with disorders of impulsivity and decision-making. The medial portion of the OFC

12

is connected to the hippocampus and cingulate and is involved with assessing the familiarity of a
situation to integrate outcome expectancies. The lateral portion of the OFC is connected to the
amygdala and is associated with suppressing previously rewarded responses in order to provide
terminating signals for changing behavior. The insular cortex is important for processing pain as
it receives somatosensory inputs and tends to be activated during acute anxiety. These parts of
the brain all work together in the mesolimbic dopamine pathway and can all be impacted by
exogenous opiates (Elliott et al., 2000).
GENETICS
While there are many social and economic factors that lead to differences in opioid use disorder
between racial groups and genders, there are underlying genetic factors that contribute to this
addiction pathway as well (Mistry et al., 2014). Studies of twins consistently demonstrate that
familial genetics contribute greatly to addiction (Cadoret, Troughton, & German, 1986). The
Harvard Twin Study of Substance Abuse shows that there is a 34% contribution from genetic
influences into the variance of abuse (Tsuang et al., 2001). The heritability involved with
addiction and drug use behavior is based off multiple genes, and by developing an understanding
of these genetic markers, there is the potential to change the way opioid abuse is studied and
treated.
The gene that encodes for dopamine receptor D2 (DRD2) is located on chromosome
11q23 and allows for the production of a seven-transmembrane helix receptor that can inhibit
adenylyl cyclase through inhibitory G-proteins (Freedman et al., 1994). The allele DRD2
rs1800497 contains a polymorphism that is associated with heroin dependence. The specific
polymorphism is at the Taq1 RFLP site rs1800497 and involves a single nucleotide
polymorphism (SNP). In a study that compared the allele frequencies in 500 Han Chinese opioid
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addicted subjects, the patients who carried at least one copy of this rs1800497 A1 allele had a
mean heroin consumption twice as high as those subjects without this allele (Hou & Li, 2009).
This allele is present at a higher frequency in subjects with opioid use disorder and has been
associated with successful methadone treatment outcomes (Dalley et al. 2009). In another study
involving 95 Caucasian opioid addicted subjects, 19% showed the rs1800497 A1 allele,
compared to the 4.6% occurrence that found in the control subjects with no history of addiction.
There are three different types of G-protein coupled opioid receptors – the μ, κ, and δ
receptors (Dalley et al., 2009). The gene that encodes for Opioid Receptor μ 1 (OPRM1) is
located on chromosome 6q24-q25 (Kapur et al., 2007). There have been correlations between
this gene and many physiological symptoms such as respiratory depression, decreased
gastrointestinal motility, and euphoria (Dalley et al., 2009). There are many SNPs present
between ethnic variations with opioid abuse and general opioid abuse (Kapur et al., 2007). In an
analysis of Hispanic subjects, the SNP occurring at A118G (rs1799971) was significantly higher
in those without any opioid dependency. In a study involving Indian subjects, there was a 31%
frequency in the A118G SNP gene for those that were opioid dependent (Dond et al., 1998).
Other than the receptors themselves, neurotrophic factors also play a regulatory role in
the nervous system. Brain-derived neurotrophic factor (BDNF) is a protein linked to opioid
dependence and is encoded by the BDNF gene, which is located on chromosome 11p14 (de Cid
et al., 2008). Connecting drug use and drug dependence, this protein is imperative in the reward
pathway and regulating cellular signals. Increased concentrations of BDNF in the ventral
tegmental area induce over-expression of dopamine receptors leading to a reward state parallel to
the type achieved with opioid use (Heidt et al., 2007). In a study with Japanese subjects, an SNP
of the gene G196A (rs6265) indicated a link between depression and genotypes. With female
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subjects that were homozygous for the G196A allele that encoded for valine, there was a
significant increase for reward dependence and extraversion, which negatively correlates to
depression. In contrast, subjects that carried the SNP for methionine were more prone to
developing depression-related mood disorders. Subjects with the G196A valine allele showed
increased levels of BDNF, which leads to increased euphoric events (Itoh et al., 2004).
INTRODUCTION TO PUBLIC HEALTH CONCERNS
The number of deaths that occurred in the United States from prescription opioids more than
quadrupled between 1999-2010 (Volkow et al., 2014). The Council of Economic Advisors
estimates that in 2015 the economic cost of the opioid crisis was $504 billion, or 2.8 percent of
GDP that year (Council of Economic Advisors, 2017). A majority of these costs are attributed to
nonfatal consequences such as healthcare spending, criminal justice costs, fatality costs, and lost
productivity due to incarceration and addiction (Florence et al., 2016). The outcomes of
increased opioid consumption include sharp increases in emergency room visits for overdose,
neonatal abstinence syndrome, and increased mortality (SAMHSA, 2013). With an increase in
morbidity and mortality rates due to opioids, it is necessary to utilize a multi-faceted public
health approach that employs addiction prevention strategies.
IMPACT ON HEROIN USE
The opioid pain relievers (OPR) overdose death rate nearly quadrupled from 1999-2011 (Chen et
al., 2014), as shown in Figure 6, and is now cited by the Centers for Disease Control and
Prevention (CDC) as the “worst drug overdose epidemic in [US] history” (Paulozzi, 2010). It is
important to recognize the relation between OPRs and heroin use. Statistics from the National
Survey on Drug Use and Health (NSDUH) indicate 4 out of 5 heroin users began their addiction
with OPRs and switched drugs because heroin was cheaper and easier to obtain (Muhuri et al.,
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2013). In 2014, national surveillance data showed that 914,000 individuals reported using heroin,
which was a 145% increase from seven years prior (Center for Behavioral Health Statistics and
Quality, 2014). When looking at the drug overdose crisis holistically, it is necessary to
understand the relationship between heroin and opioids to avoid the error of shifting the problem
from one drug to another unintentionally.

Figure 6: Three Wave Rise of Opioid Use
This graph overlays the increases of Heroin, Prescription Opioids, and Other Synthetic Opioids
outlined in three distinct waves. The first wave began with the increased prescriptions for opioids
which increased until 2010. This was when the prescriptions decreased yet patients remained
addicted, many of them switched to heroin which is depicted by the rapid increase in overdose
deaths.
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HISTORY OF OPIOID ADDICTION IN THE UNITED STATES
In the 1840s, there was an increase in the estimated national supply of opium and morphine
imports, which throughout the next 50 years lead to a 538% increase in opioid consumption
(Courtwright, 2001). There were many uses for the drug, including the common use of opium by
soldiers to treat painful injuries. Physicians at this time often prescribed opiates to their patients
as there were few alternatives and the etiology of many chronic and acute diseases were poorly
understood. As many advancements in health occurred, the administration of morphine as a
primary solution decreased through the means of educated, better-trained health practitioners
(Blair, 1919). The rest of the 20th century saw the use of short-lasting, nonmedical opioid
increase disproportionately in inner-city, minority populations (DuPont & Greene, 1973).
In 1996, the rate of opioid use began accelerating rapidly due in part to the introduction
of OxyContin in 1995 by Purdue Pharma. This drug is an extended-release formula for morphine
advertised under the claim that the risk of addiction was minimal to none. Indeed, OxyContin
was advertised as appropriate for the treatment of chronic pain. In the seven years that followed
the introduction of OxyContin, Purdue Pharma funded over 20,000 educational programs that
encouraged the long-term use of OPRs for non-cancer related chronic pain (US GAO). Purdue
Pharma financially supported groups such as The Joint Commission, the Federation of State
Medical Boards, the American Academy of Pain Medicine, and the American Pain Society – all
of whom advocated for the use of OPRs to treat pain (Fauber, 2012). In 2007, the executives of
Purdue Pharma pleaded guilty in federal court to criminal charges about misleading health
professionals and patients about OxyContin, and they agreed to pay $600 million in fines, one of
the largest amounts paid by any drug company. The executives agreed to pay a total of $34.5
million in fines for misbranding, which is a criminal violation (Meier, 2007).
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While there have been no long-term quality clinical trials on the efficacy of OPRs for
non-cancer chronic pain, there have been surveys of patients indicating that even with opiates
they still experience significant chronic pain (Eriksen et al., 2006). The Joint Commission’s
federally mandated patient satisfaction surveys ask patients to rate how their experience in the
hospital was related to pain. This experience relates to the increase in hospital use of OPRs as
physicians administer more opiates to have patients provide higher ratings (Herzig et al., 2014).
Overall, the United States has had a complicated relationship with opioid use. In recent
history, the rise in opioid overdose death has had three distinct waves, initially in the 1990s with
the over-prescription of opioids. The second wave was in 2010 when there was a rapid increase
in heroin deaths. The third wave since 2013 includes a rapid increase in overdose deaths due to
synthetic opioids such as fentanyl (Centers for Disease Control and Prevention, 2017).
WHO IS USING?
From 2002 to 2012, the use of nonmedical opioids has gradually declined; however, overdose
deaths, addiction treatment admissions, and other adverse public health outcomes related to
OPRs have increased (SAMHSA (Substance Abuse Ment. Health Serv. Adm.), 2003).
The demographic that abuses non-medically prescribed opioids the most is the young
adult population, age 18-25. However, the group with the greatest use of prescription opioids is
among adults over the age of 26 (CDC, 2016). From 2013-2014 the rate of opioid overdose
deaths for men was three times higher than those of women for populations age 18-34 within the
state of Massachusetts (Massachusetts Department of Public Health, 2016).
One study looking at unintentional opioid overdoses in Utah showed that 92% of those
who had died from overdose were receiving legitimate opioid prescriptions for their chronic
pain. Middle-aged white women aged 55-64 and the elderly visit their physicians with
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complaints of pain the most frequently, with rates higher than any other demographic (Blackwell
et al., 2014). White women aged 55-64 have experienced the largest increase in accidental opioid
overdose deaths over the past decade (CDC, 2013). Death from overdose can occur in non-opioid
addicted users, yet it is much more common in individuals who are addicted to opioids.

Figure 7: National Overdose Deaths 2002-Provisional 2017 Involving Opioids
This bar graph depicts the total number of overdose deaths in the United States that were
involving opioid drugs with provisional data from 2017. A line overlay depicting male versus
female deaths further divides this graph. There has been a 4.1-fold increase in the total number of
deaths involving opioids in the time depicted.

NATIONAL RESPONSE
In October of 2017, the acting Health and Human Services (HHS) Secretary declared the opioid
crisis a nationwide public health emergency. In April of the same year, the HHS presented a new
19

five-point Opioid Strategy. The priorities include: (1) improving access to prevention, treatment,
and recovery support services; (2) targeting the availability and distribution of overdosereversing drugs; (3) strengthening public health data and collection; (4) supporting cutting-edge
research on addiction and pain; and (5) advancing the practice of pain management (U.S.
Department of Health and Human Services, 2018).
To improve access to treatment and recovery support services, the HHS submitted letters
to the governors in every U.S. state offering $485 million in grant money in return for evidencebased treatment and prevention activities. These grants from the Substance Abuse and Mental
Health Services Administration complemented grants from the Comprehensive Addiction and
Recovery Act (CARA). By providing the funds for a wide range of programs – training for
health professionals, prevention programs, technological support, and monitoring programs –
there is a focus on recognizing that individual states will tackle their state-wide crises at a level
that is specific for their communities (Secretary for Health and Human Services, 2018). Many
states have given importance to opioid overdose reversal drugs such as naloxone. These drugs
can reverse the effect of overdoses, and there is a focus on making them as affordable as possible
while increasing access to them (Secretary for Health and Human Services, 2018).
The third priority in the Opioid Strategy is that of public health surveillance and research.
A goal of the HHS is to increase cooperation between public health authorities and law
enforcement. To accomplish this, the HHS is working with Customs and Border Protection, so
that when shipments of opioids are intercepted, the local public health authorities are alerted in
order to help them best prepare for an upcoming wave of overdoses (Secretary for Health and
Human Services, 2018).
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Pain management is an incredibly important component in the discussion of finding
lasting solutions for the opioid crisis. It is necessary to avoid creating dependence in the first
place, including rethinking and revisiting the revolution that has occurred in pain management
over the past several years. The Office of Assistant Secretary and the National Institute of Health
(NIH) are working through the Interagency Task Force on Pain Management to implement a
National Pain Strategy (Secretary for Health and Human Services, 2018).
OVERDOSE TREATMENTS
Morphine is an agonist at the mu-opioid receptor and by functioning as an antagonist at the muopioid receptor; drugs such as naloxone can reverse overdoses. Naloxone has saved tens of
thousands of lives, but administration must occur shortly after an overdose (Volkow & Francis,
2017). There is a necessity for newer improved reversal drugs. The National Institute on Drug
Abuse (NIDA) developed a Narcan Nasal Spray, which functions as an intranasal naloxone
formula. This spray was an advancement in the field of treatments, as it would result in blood
naloxone levels that were equivalent to if the naloxone had been administered parenterally. This
drug is also available in an injection form. Some longer-term alternatives that will potentially be
able to intervene against opioid-induced respiratory depression include 5-hydroxytryptamine
type 1A (5-HT1A) agonists, ampakines, and phrenic-nerve-stimulation devices. These treatments
would be most effective for those individuals that are at high risk for overdose (Volkow &
Francis 2017).
OPIOID USE DISORDER TREATMENTS
There is no immediate solution for opioid addiction treatment. To maintain long-term recovery,
sustained treatment over a prolonged period is necessary. However, three medications that are
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approved for opioid use disorder: methadone via methadone maintenance treatments,
buprenorphine, and extended-release naltrexone (Volkow et al., 2014).
Methadone Maintenance Treatment (MMT) involves having the opioid-dependent
individual orally consume a daily dose of methadone under medical supervision. This treatment
method aids in decreasing criminal activity often associated with obtaining illegal drugs (Volkow
& Francis, 2017). There has been a development with buprenorphine treatment, which functions
as a partial opioid agonist, which will produce lower levels of the side effects when compared to
other opioids such as oxycodone and heroin. NIDA collaborated with pharmaceutical industries
to develop an implant, Probuphine, which would deliver doses on a weekly or monthly period to
the individual. This is an initial step towards long-term treatment methods and would work well
for patients that have had nonfatal opioid overdoses (Volkow & Francis, 2017). Extended-release
naltrexone is a monthly injectable formula of the mu-opioid receptor antagonist that is also used
to prevent opioid dependence. There has been much promise shown for vaccines against
prescription opioids, synthetic opioids, and heroin. These vaccines would function by inducing
antibodies to prevent opioids from entering the brain (Bremer et al., 2016).
CONCLUSION
The opioid epidemic was not created in a vacuum. Surgeon and author Atul Gawande
stated in an interview that it was doctors who have started the epidemic and it began as an effort
to better treat pain, something that had previously been undertreated (Kliff, 2017). Moving
forward it is important for the American Medical Association to ensure that physicians who are
practicing in the United States are actively monitoring their patients and have safe methods to
report any suspicious patterns. It is also necessary to create and enforce policies for healthcare
providers that reflect the guidelines that are put in place from organizations such as the Centers
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for Disease Control and Prevention. Pharmaceutical companies have also fueled the epidemic by
using aggressive techniques to boost prescriptions. The American Pharmacists Association
should focus on research that provides safer alternatives to opioid use for pain and couple these
less aggressive pain treatments with ensuring that for those that are currently addicted, there are
alternative medications at an affordable rate. A look at socioeconomic factors is also important,
as a lack of health insurance, poverty, and unemployment are associated with a higher prevalence
of prescription opioid disorder (Godlee, 2017). No biological treatment will address the lack of
economic opportunity, and this will require action at an institutional level. Many insurance
policies do not cover addiction treatments, and many individuals facing this crisis lack insurance.
Nationally, a look towards expanding Medicaid will aid in increasing access to health insurance
and should cover not just treatment but also preventive care. To create a more comprehensive
opioid strategy, it will be necessary to build coalitions and partnerships with all the stakeholders
involved through a collective impact model to guide decision making and collaborative
approaches.
From the public health perspective, one of the solutions for many of the issues involved
with this epidemic is that of improving accessibility and surveillance of data at local levels. By
having data-driven frameworks present at local levels, interventions will be more adaptive to
their respective regions and can be monitored for successes. It will also promote collaboration
between the different areas that are involved in finding solutions- research, industry, and
government.
Throughout the history of medicine, one of the strongest allies in resolving public health
crises has been the field of science. With regards to the opioid epidemic, science needs to be at
the forefront of the discussion regarding treatment. It is necessary to increase inter-agency
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collaboration and recognize the true extent that this crisis spans. This current epidemic is
multifaceted and involves many different agencies: pharmaceutical companies, medical
professionals, educators, border control agents, governmental agencies such as the FDA &
NIDA, law enforcement, and scientists. Better coordination of community involvement and
allocating funds towards appropriate resources are some initial steps that should be taken to
combat this epidemic. Finding alternate solutions to pain management that do not involve the
administration of addictive opioids is imperative. Looking forward, a public health approach that
focuses on evidence-based scientific tools will help to end this current crisis and prevent it from
reemerging in the future.
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